AOD 9604 5mg research peptide is supplied by Biotech Peptides for qualified laboratory and analytical work. AOD 9604 is a synthetic peptide based on the C-terminal region of human growth hormone (hGH), covering residues 177–191 with an additional tyrosine at the N-terminus. Researchers have examined this sequence in relation to lipid metabolism, peptide characterisation, in-vitro metabolism and experimental cartilage models. The available evidence remains investigational and does not establish AOD 9604 as an approved treatment for weight loss, obesity, osteoarthritis or any other condition.
This page separates established chemical information from early-stage findings so researchers can assess the material responsibly. Biotech Peptides supplies this 5mg product strictly for laboratory research. It is not a medicine, food, cosmetic, supplement or veterinary product and is not intended for human or animal consumption.
AOD 9604 5mg product overview
- Product name: AOD 9604
- Presentation: 5mg lyophilised research material
- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Reported molecular formula: C78H123N23O23S2
- Reported molecular mass: approximately 1815.1 g/mol
- Research classification: synthetic hGH C-terminal fragment
- Intended use: laboratory research and analytical applications only
- Not intended for: human use, animal use, diagnostic use or therapeutic use
Researchers should confirm identity, purity, mass and handling requirements against the documentation supplied with the specific batch. Values in scientific literature may vary with salt form, hydration state, analytical method and reporting convention. Product documentation, rather than a general web page, should guide batch-specific analytical decisions.
What is AOD 9604 5mg?
AOD 9604 is a 16-amino-acid peptide derived from a region at the carboxyl terminus of human growth hormone. It incorporates the hGH 177–191 sequence and adds a tyrosine residue at the N-terminus. This structural relationship explains why scientific papers sometimes refer to AOD 9604 as a modified growth-hormone fragment. It should not be described as full-length growth hormone, and evidence concerning hGH cannot automatically be applied to this shorter peptide.
The compound emerged from research exploring whether individual domains of the much larger hGH molecule might be associated with distinct biological effects. Early preclinical work focused on lipid metabolism and energy balance. Later analytical studies examined detection and in-vitro metabolism, while separate animal studies investigated experimental osteoarthritis models. These research streams address different questions and should not be blended into a single therapeutic claim.
AOD 9604 5mg structure and sequence
The sequence of AOD 9604 is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. Its two cysteine residues are important when considering structure, oxidation state and analytical handling. The peptide’s identity should be evaluated using appropriate laboratory methods such as mass spectrometry and chromatographic analysis where required by the study design.
AOD 9604 is distinct from hGH 176–191 and from unmodified hGH 177–191, even though these names are sometimes used loosely online. Researchers should record the exact sequence, form and batch identifier in protocols to support reproducibility. Substituting one fragment name for another can introduce avoidable ambiguity when comparing studies.
What researchers have studied about AOD 9604 5mg
Published research has explored AOD 9604 across several experimental settings. Metabolic studies investigated the behaviour of the modified hGH domain in animal models and laboratory systems. Mouse studies assessed body weight, substrate oxidation and energy balance. Analytical research examined detection and in-vitro metabolism. A rabbit study evaluated intra-articular administration in a collagenase-induced osteoarthritis model.
These findings are not equivalent to proof of clinical efficacy. Animal-model outcomes may help generate hypotheses, but differences in physiology, experimental conditions, route of administration and exposure limit direct translation to people. In-vitro findings show what occurs under controlled laboratory conditions and cannot by themselves establish safety or benefit in a living organism.
AOD 9604 5mg and lipid-metabolism research
Early research examined whether the C-terminal domain of hGH could influence lipid metabolism without reproducing every action associated with full-length growth hormone. One published metabolic study assessed a synthetic lipolytic domain in animal and cellular research. Another chronic-treatment study compared hGH and AOD 9604 in obese and lean mice, examining body weight, energy balance and substrate oxidation.
Those experiments are relevant to the history of the compound, but they should be described with careful qualifiers. Results from genetically or experimentally selected mouse models do not establish a weight-loss effect in humans. Online statements that guarantee fat loss, specify expected percentages or present AOD 9604 as a proven obesity treatment go beyond the strength of the evidence.
For rigorous work, researchers should document species, strain, sex, age, metabolic status, comparator, exposure conditions and outcome measures. Those variables can materially affect interpretation. Replication and suitable controls are essential, particularly when an experiment seeks to distinguish peptide-specific effects from changes caused by handling, diet, vehicle or other study conditions.
Relationship to growth-hormone signalling
AOD 9604 is structurally related to part of hGH, but structural origin does not make it functionally identical to the intact hormone. Scientific discussion has examined whether selected metabolic observations occur independently of classical growth-hormone receptor effects. The correct conclusion is that this remains a research question shaped by the model and assay being used.
Product descriptions should therefore avoid promising muscle growth, increased IGF-1, appetite suppression, glucose control or hormone replacement effects. Claims about full-length hGH cannot simply be transferred to a fragment. Researchers should test the mechanism relevant to their own protocol rather than assume a pathway from marketing language.
Analytical detection and in-vitro metabolism
A peer-reviewed study published in Drug Testing and Analysis described detection and in-vitro metabolism of AOD 9604. This work is useful for laboratories interested in peptide identification, transformation products and analytical workflows. It also reinforces the importance of using sequence-specific and method-appropriate standards.
Analytical laboratories may consider chromatographic separation, mass-spectrometric confirmation, reference controls and documented sample preparation. The exact method should be selected and validated for the intended matrix and research question. A general product page cannot replace a laboratory’s validated method, quality system or risk assessment.
Preclinical cartilage and osteoarthritis research
AOD 9604 has also been studied in a collagenase-induced rabbit knee osteoarthritis model, alone and with hyaluronic acid. The publication reported findings related to cartilage regeneration within that experimental model. This was animal research involving intra-articular administration; it does not demonstrate that AOD 9604 is a safe or effective treatment for osteoarthritis in people.
The distinction matters. Cartilage outcomes in rabbits depend on the induced model, intervention conditions, assessment method and follow-up period. Human clinical claims require suitable controlled trials and regulatory review. Biotech Peptides does not recommend or support medical, veterinary or self-experimental use.
Evidence limitations
The AOD 9604 evidence base includes preclinical studies and limited human investigation, but it does not justify definitive therapeutic promises. Several limitations should be considered:
- Many frequently cited findings come from mice, rats, rabbits or in-vitro systems.
- Experimental outcomes may depend on route, exposure, formulation and model.
- Mechanistic observations do not automatically translate into clinical benefit.
- Published abstracts and secondary summaries may omit important protocol details.
- Safety information for unapproved routes and formulations is incomplete.
- Commercial claims online often exceed what peer-reviewed evidence supports.
The US Food and Drug Administration has identified potential safety concerns involving compounded AOD 9604, including immunogenicity, peptide-related impurities and active-ingredient characterisation. It has also noted reports of serious adverse events for which causality was unclear. Although this is a UK-focused research product page, those observations are relevant when explaining why non-research use and unsupported safety claims are inappropriate.
Laboratory quality considerations
Peptide research depends on traceability and fit-for-purpose analytical controls. Before beginning an experiment, a qualified researcher should review the batch documentation, intended assay, storage conditions and laboratory safety procedures. Identity and purity are different attributes: a sample may contain the expected peptide while also containing related impurities, degradation products or residual process materials.
Good documentation should connect the received vial to its batch or lot information. Records may include receipt date, storage history, preparation details, instrument method, operator, run date and raw analytical data. This supports reproducibility and helps investigators distinguish a biological result from a sample-handling or method issue.
AOD 9604 5mg storage and handling
Keep the unopened research material under the conditions stated on its product label and batch documentation. Protect it from conditions that may promote degradation, including inappropriate heat, moisture or repeated temperature changes. Laboratory personnel should minimise unnecessary handling and use clean, suitable equipment.
Any preparation of the material must follow an institutionally approved protocol created by a qualified professional. This page intentionally does not provide instructions for injection, human dosing, self-administration or therapeutic use. Prepared samples may have different stability characteristics from lyophilised material, so researchers should rely on validated stability information rather than assumptions.
AOD 9604 5mg research-use-only requirements
AOD 9604 5mg is offered only for legitimate laboratory and analytical research. It must not be used as a medicine, supplement, cosmetic ingredient, food ingredient or veterinary treatment. It is not intended to diagnose, treat, cure or prevent disease. It must not be administered to humans or animals.
Purchasers are responsible for confirming that acquisition, possession, storage and use comply with applicable institutional policies and local law. A “research use only” label is a substantive limitation, not a substitute for regulatory authorisation. Researchers working with investigational medicinal products in the UK may require formal approvals and must follow the relevant regulatory framework.
Why choose Biotech Peptides for AOD 9604 5mg?
Biotech Peptides presents this product with clear research-only boundaries and evidence-led information. The page identifies the peptide sequence, distinguishes preclinical findings from clinical proof and avoids unsupported promises. Researchers can explore the wider Biotech Peptides research catalogue or review information about Biotech Peptides before selecting material for an approved laboratory protocol.
Product price, availability and batch documentation should be reviewed at the time of ordering. Research suitability depends on the purchaser’s protocol, facilities, expertise and compliance obligations. The presence of a product in the catalogue does not imply therapeutic approval.
AOD 9604 research references
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274–278. PubMed record.
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001;25(10):1442–1449. PubMed record.
- Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015;7(1):31–38. PubMed record.
- Kim JH, et al. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model. PubMed record.
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA safety information.
Frequently asked questions
1. What is AOD 9604?
AOD 9604 is a synthetic 16-amino-acid peptide based on the C-terminal region of human growth hormone. It contains the hGH 177–191 sequence with an additional N-terminal tyrosine.
2. What does the 5mg label mean?
It identifies the nominal quantity of lyophilised research material in the product presentation. Researchers should consult the batch documentation for product-specific analytical information.
3. Is AOD 9604 the same as full-length growth hormone?
No. It is a short modified fragment derived from one region of hGH. Findings concerning intact growth hormone cannot automatically be attributed to AOD 9604.
4. Is AOD 9604 approved for weight loss?
This product is not presented as an approved medicine or weight-loss treatment. The available literature includes experimental metabolic research, much of it preclinical, and does not justify guaranteed human outcomes.
5. Has AOD 9604 been studied in humans?
Limited human investigation has been discussed in regulatory and scientific materials, but the evidence does not establish this research product as an approved therapy. Study design, formulation, route and regulatory status must be considered separately.
6. Has AOD 9604 been studied for cartilage?
A published rabbit osteoarthritis model examined AOD 9604 with and without hyaluronic acid. An animal-model result is not proof of safety or effectiveness in humans.
7. Can this product be used by people or animals?
No. Biotech Peptides supplies AOD 9604 5mg strictly for laboratory research and analytical use. It is not intended for human or animal consumption or administration.
8. Does this page provide dosing or reconstitution instructions?
No. Human dosing, injection and self-administration instructions would conflict with the product’s research-only status. Qualified laboratories should follow approved protocols and batch-specific documentation.
9. How should AOD 9604 research material be stored?
Follow the storage conditions printed on the product label and supplied documentation. Protect the material from inappropriate heat, moisture and repeated temperature fluctuations.
10. What should a laboratory record when using AOD 9604?
Useful records include batch identity, receipt and storage history, preparation details, controls, analytical method, instrument data, operator and experimental conditions. Complete records improve traceability and reproducibility.
Research-use disclaimer: AOD 9604 5mg is intended solely for laboratory research and analytical purposes. It is not a medicine, supplement, food, cosmetic or veterinary product. It is not intended for human or animal consumption, diagnosis or treatment.
